Elanco Animal Health Inc (ELAN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2B 4B 6B Q3 '21: 4.8B Q4 '21: 4.8B Q1 '22: 4.7B Q2 '22: 4.6B Q3 '22: 4.5B Q4 '22: 4.4B Q1 '23: 4.4B Q2 '23: 4.3B Q3 '23: 4.4B Q4 '23: 4.4B Q1 '24: 4.4B Q2 '24: 4.5B Q3 '24: 4.5B Q4 '24: 4.4B Q1 '25: 4.4B Q2 '25: 4.5B Q3 '25: 4.6B Q4 '25: 4.7B Q1 '26: 4.9B Q2 '26: 5B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 1B 2B 3B Q4 '24: 2.4B Q1 '25: 2.4B Q2 '25: 2.5B Q3 '25: 2.5B Q4 '25: 2.6B Q1 '26: 2.7B Q2 '26: 2.8B Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Net Income TTM

-1.5B -1B -500M 0 500M 1B 1.5B Q3 '21: -697.8M Q4 '21: -480M Q1 '22: -368M Q2 '22: -168M Q3 '22: -129M Q4 '22: -78M Q1 '23: -26M Q2 '23: -113M Q3 '23: -1.1B Q4 '23: -1.2B Q1 '24: -1.3B Q2 '24: -1.3B Q3 '24: 205M Q4 '24: 338M Q1 '25: 373M Q2 '25: 434M Q3 '25: 36M Q4 '25: -232M Q1 '26: -242M Q2 '26: -199M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 800M 1.6B 2.4B Q3 '21: 2.2B Q4 '21: 2.1B Q1 '22: 2.1B Q2 '22: 2B Q3 '22: 2B Q4 '22: 1.9B Q1 '23: 1.9B Q2 '23: 1.8B Q3 '23: 1.9B Q4 '23: 1.9B Q1 '24: 2B Q2 '24: 2B Q3 '24: 2B Q4 '24: 2B Q1 '25: 2B Q2 '25: 2B Q3 '25: 2.1B Q4 '25: 2.1B Q1 '26: 2.2B Q2 '26: 2.2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

0 250M 500M 750M Q3 '21: 167M Q4 '21: 483M Q1 '22: 399M Q2 '22: 562M Q3 '22: 662M Q4 '22: 452M Q1 '23: 369M Q2 '23: 118M Q3 '23: 127M Q4 '23: 271M Q1 '24: 418M Q2 '24: 557M Q3 '24: 521M Q4 '24: 541M Q1 '25: 535M Q2 '25: 572M Q3 '25: 629M Q4 '25: 560M Q1 '26: 577M Q2 '26: 617M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-200M 0 200M 400M 600M Q3 '21: -12M Q4 '21: 324M Q1 '22: 239M Q2 '22: 393M Q3 '22: 492M Q4 '22: 281M Q1 '23: 193M Q2 '23: -74M Q3 '23: -72M Q4 '23: 131M Q1 '24: 278M Q2 '24: 425M Q3 '24: 380M Q4 '24: 394M Q1 '25: 347M Q2 '25: 361M Q3 '25: 368M Q4 '25: 284M Q1 '26: 315M Q2 '26: 379M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q2 '20: 413.2M Q3 '20: 462.4M Q1 '21: 486.7M Q2 '21: 487.3M Q3 '21: 487.3M Q4 '21: 487.4M Q1 '22: 492.2M Q2 '22: 488.4M Q3 '22: 488.4M Q1 '23: 492.8M Q2 '23: 492.6M Q3 '23: 492.7M Q1 '24: 496M Q2 '24: 494.2M Q3 '24: 497.7M Q1 '25: 499.1M Q2 '25: 500.1M Q3 '25: 496.8M Q1 '26: 506M Q2 '26: 505.9M Q3 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q3 '21: -1.50 Q4 '21: -0.98 Q1 '22: -0.76 Q2 '22: -0.35 Q3 '22: -0.27 Q4 '22: -0.16 Q1 '23: -0.05 Q2 '23: -0.23 Q3 '23: -2.32 Q4 '23: -2.50 Q1 '24: -2.65 Q2 '24: -2.55 Q3 '24: 0.40 Q4 '24: 0.67 Q1 '25: 0.74 Q2 '25: 0.86 Q3 '25: 0.06 Q4 '25: -0.48 Q1 '26: -0.50 Q2 '26: -0.41 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.